Related Experiment Video
Updated: Aug 29, 2026

Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
The role of B-type natriuretic peptide in heart failure
1Department of Pharmacy Practice, College of Pharmacy, Medical University of South Carolina, 43 Sabin Street, Charleston, SC 29425, USA. nappijm@musc.edu
Abstract:
The use of BNP as a diagnostic and therapeutic tool in the management of heart failure is promising. Additional studies need to be done regarding the use of BNP as a diagnostic tool to clarify its intrapatient and interpatient variability, especially over time. Nesiritide is the first new intravenous agent for the treatment of acute decompensated heart failure since the introduction of milrinone. It is an effective vasodilator and enhances the effect of concomitant diuretic therapy. Nesiritide may have some benefit on long-term outcomes by prolonging survival, decreasing hospitalizations, or enhancing quality of life. Whether it can or should be used as chronic therapy in end-stage patients remains to be determined.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure Drugs: β-Blockers
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VII: Nursing Interventions
Heart Failure Drugs: Diuretics
